Screening, American Thyroid Association Guidelines, and Initial Management

Systematic screening for thyroid eye disease in patients with thyroid dysfunction has become a priority as practice guidelines evolve. In this segment, Andrea Kossler, MD, discusses how the 2022 American Thyroid Association (ATA) guidelines recommending TED screening for all patients with thyroid disease have shaped her clinical approach. Rather than limiting screening to those with overt ocular complaints, she now uses each visit as an opportunity for structured education and symptom review.

Dr Kossler describes a pragmatic workflow for patients with newly diagnosed Graves disease. Even before the formal examination, she observes patients’ eyes as they enter the room, looking for obvious signs of TED. She then incorporates targeted questions regarding dryness, grittiness, tearing, pressure, and other ocular surface or orbital symptoms. Depending on the responses, she tailors additional questioning and counseling, focusing on modifiable risk factors such as smoking cessation, head-of-bed elevation, and liberal use of lubricating eye drops.

Initial management, as described by Andrea Kossler, MD, centers on optimizing thyroid function and addressing early ocular symptoms. She notes that achieving a euthyroid state may attenuate inflammation and improve ocular manifestations over time. In selected patients with more significant or bothersome symptoms, she considers short courses of corticosteroids and introduces discussion of emerging systemic therapies, while reinforcing the importance of close follow-up and coordination with eye care specialists.

Andrea Kossler, MD, situates her screening practices within the framework of the 2022 American Thyroid Association guidelines, which recommend that all patients with thyroid disease be assessed for thyroid eye disease. This universal screening strategy represents a shift from prior, more selective approaches and reflects an emphasis on early detection and patient education. In her practice, screening is integrated into routine consultations, with an emphasis on both clinical observation and structured symptom inquiry.

Her workflow begins with informal visual inspection of the patient as they enter the clinic, noting any overt orbital or eyelid abnormalities. Formal screening then proceeds with standardized questions about ocular surface symptoms (eg, dryness, foreign body sensation, tearing) and orbital complaints (eg, pressure, discomfort). Positive responses trigger a more detailed assessment, including evaluation of disease activity, severity, and impact on quality of life. This stepwise approach helps triage patients for more aggressive assessment or early referral.

From a management standpoint, Dr Kossler stresses that normalizing thyroid function is foundational, as restoration of euthyroidism may diminish immunologic activity and ameliorate ocular findings. In addition, she institutes simple adjunctive measures such as nighttime head-of-bed elevation, frequent use of lubricating eye drops, and strong encouragement of smoking cessation. For patients with more symptomatic disease, she considers systemic corticosteroids while also educating them about newer targeted options. This framework reflects a proactive, guideline-concordant model aimed at intercepting TED before irreversible structural changes occur.